{"id":"tbe-booster-vaccination","safety":{"commonSideEffects":[{"rate":"10–30%","effect":"Injection site pain, redness, or swelling"},{"rate":"5–15%","effect":"Headache"},{"rate":"5–15%","effect":"Myalgia or fatigue"},{"rate":"1–5%","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TBE booster vaccination contains inactivated tick-borne encephalitis virus antigen that triggers both humoral (antibody) and cell-mediated immune responses. Booster doses are administered at intervals to maintain or enhance protective antibody titers against TBE virus infection. This approach ensures sustained immunity against the virus transmitted by infected ticks in endemic regions.","oneSentence":"TBE booster vaccination stimulates the immune system to produce antibodies and cellular immunity against tick-borne encephalitis virus through repeated antigen exposure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:23.878Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Booster vaccination for tick-borne encephalitis (TBE) prevention in previously vaccinated individuals"}]},"trialDetails":[{"nctId":"NCT01562444","phase":"PHASE4","title":"Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-03-08","conditions":"Tick Borne Encephalitis, Virus Diseases","enrollment":206},{"nctId":"NCT01582698","phase":"PHASE4","title":"TBE Seropersistence up to 10 Years After First Booster in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04","conditions":"Tick-borne Encephalitis (TBE)","enrollment":243},{"nctId":"NCT02511535","phase":"PHASE4","title":"TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-09","conditions":"Vaccine Responsiveness in Allergy, Vaccine Responsiveness During Allergy De-sensitization Treatment","enrollment":119},{"nctId":"NCT04017052","phase":"PHASE4","title":"Application of a TBE-Vaccine in Obese Persons","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2015-04-15","conditions":"Tick Borne Encephalitis","enrollment":73},{"nctId":"NCT00894686","phase":"PHASE4","title":"Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-04-26","conditions":"Encephalitis, Tick-Borne","enrollment":179},{"nctId":"NCT01031537","phase":"PHASE2","title":"Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-09-25","conditions":"Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease","enrollment":69},{"nctId":"NCT00161785","phase":"PHASE4","title":"Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-06","conditions":"Tick-borne Encephalitis","enrollment":340},{"nctId":"NCT00163618","phase":"","title":"Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-06","conditions":"Encephalitis, Tick-borne","enrollment":""},{"nctId":"NCT00161967","phase":"PHASE4","title":"TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-05","conditions":"Encephalitis, Tick-Borne","enrollment":375},{"nctId":"NCT00503529","phase":"PHASE4","title":"TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-07","conditions":"Encephalitis, Tick-Borne","enrollment":314},{"nctId":"NCT00387634","phase":"PHASE4","title":"Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-09","conditions":"Tick Born Encephalitis","enrollment":323},{"nctId":"NCT00452621","phase":"PHASE4","title":"Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Encephalitis, Tick-Borne","enrollment":235},{"nctId":"NCT00311493","phase":"PHASE4","title":"Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-02","conditions":"Encephalitis, Tick-Borne","enrollment":179}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vaccine: FSME-Immun® (Fruehsommer-Meningoencephalitis)","One dose (0.5 ml) contains:","2.4 micrograms Tick-Borne Encephalitis Virus ( strain Neudoerfl),","adsorbed on aluminium oxide, hydrated (0.35 milligrams Al3+)","Manufacturer: Baxter Innovations GmbH"],"phase":"marketed","status":"active","brandName":"TBE booster vaccination","genericName":"TBE booster vaccination","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Biologic","firstApprovalDate":"","aiSummary":"TBE booster vaccination stimulates the immune system to produce antibodies and cellular immunity against tick-borne encephalitis virus through repeated antigen exposure. Used for Booster vaccination for tick-borne encephalitis (TBE) prevention in previously vaccinated individuals.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}